NasdaqGS:VRTXBiotechs
Vertex Pharmaceuticals (VRTX) Valuation Check After Q4 Beat And Growing Confidence In Povetacicept
Vertex Pharmaceuticals (VRTX) is back in focus after reporting fiscal Q4 results that topped earnings and revenue expectations, drawing fresh attention to its late stage pipeline, including povetacicept in primary membranous nephropathy.
See our latest analysis for Vertex Pharmaceuticals.
The Q4 beat and renewed interest in povetacicept come as Vertex’s shares trade around US$486.03, with a 30 day share price return of 3.43% and a 90 day share price return of 12.21%. The 3 year total...